Colleen Craig
Vice President, Metabolic Diseases at Eiger BioPharmaceuticals, Inc. - Palo Alto, CA, US
Colleen Craig's Colleagues at Eiger BioPharmaceuticals, Inc.
Colleen Craig's Contact Details
650-272-6138
Eiger BioPharmaceuticals, Inc.
Colleen Craig's Company Details
Eiger is a commercial-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases. All five Eiger rare disease programs have been granted FDA breakthrough therapy designation. Eiger's lead clinical programs are focused on the development of innovative therapies to treat and cure hepatitis delta virus (HDV) infection, the most serious form of viral hepatitis. Our HDV platform includes two first-in-class therapies in Phase 3 that target critical host processes involved in viral replication. Eiger is also developing peginterferon lambda as a therapeutic for COVID-19 and is planning to submit an emergency use application to FDA based on positive results from the investigator sponsored Phase 3 TOGETHER study. Eiger's first FDA approved therapy is Zokinvy for the treatment of Hutchinson-Gilford Progeria Syndrome (HGPS or Progeria). A Marketing Authorization Application (MAA) is under review by the European Medicines Agency (EMA). For additional information about Eiger and its clinical programs, please visit www.eigerbio.com.